VICP Registry Case Source Bundle Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_18-vv-00622 Package ID: USCOURTS-cofc-1_18-vv-00622 Petitioner: Katherine L. Alberino Filed: 2018-05-02 Decided: 2020-02-27 Vaccine: Tdap Vaccination date: 2017-08-22 Condition: Guillain-Barré syndrome (“GBS”) with residual effects that persisted for more than six months Outcome: compensated Award amount USD: 155000 AI-assisted case summary: Katherine L. Alberino filed a petition for compensation on May 2, 2018, alleging that she developed Guillain-Barré syndrome (GBS) with residual effects that persisted for more than six months after receiving a tetanus-diphtheria-acellular pertussis (Tdap) vaccine on August 22, 2017. The respondent, the Secretary of Health and Human Services, denied that the Tdap immunization caused or significantly aggravated petitioner's alleged GBS or any other injury or condition. Despite maintaining their respective positions, the parties reached a stipulation for settlement. On February 27, 2020, Special Master Thomas L. Gowen adopted the stipulation, which awarded Katherine L. Alberino a lump sum of $155,000.00 for all damages. The decision does not describe the specific onset of symptoms, clinical course, diagnostic tests, treatments, or expert witnesses. Petitioner was represented by William E. Cochran Jr. of Black McLaren, et al., PC, and respondent was represented by Camille C. Collett of the United States Department of Justice. Theory of causation field: Petitioner Katherine L. Alberino alleged that a Tdap vaccine administered on August 22, 2017, caused Guillain-Barré syndrome (GBS) with residual effects persisting for more than six months. Respondent denied causation. The parties reached a stipulation for settlement, and Special Master Thomas L. Gowen awarded compensation. The public decision does not detail the specific theory of causation, mechanism, expert testimony, or the breakdown of the $155,000.00 award beyond it being a lump sum for all damages. Petitioner was represented by William E. Cochran Jr., and respondent by Camille C. Collett. Public staged source text: ================================================================================ DOCUMENT 1: USCOURTS-cofc-1_18-vv-00622-0 Date issued/filed: 2020-03-20 Pages: 7 Docket text: PUBLIC DECISION (Originally filed: 2/27/20) regarding 51 DECISION on Stipulation. Signed by Special Master Thomas L. Gowen. (kb) Service on parties made. -------------------------------------------------------------------------------- Case 1:18-vv-00622-UNJ Document 55 Filed 03/20/20 Page 1 of 7 In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS Filed: February 27, 2020 * * * * * * * * * * * * * KATHERINE L. ALBERINO, * UNPUBLISHED * Petitioner, * No. 18-622V * v. * Special Master Gowen * SECRETARY OF HEALTH * Tetanus-Diphtheria-acellular AND HUMAN SERVICES, * Pertussis (“Tdap”); * Guillain-Barré syndrome Respondent. * (“GBS”). * * * * * * * * * * * * * William E. Cochran Jr., Black McLaren, et al., PC, Memphis, TN, for petitioner. Camille C. Collett, United States Department of Justice, Washington, DC, for respondent. DECISION ON STIPULATION1 On May 2, 2018, Katherine L. Alberino (“petitioner”) filed a petition for compensation within the National Vaccine Injury Compensation Program.2 Petition (ECF No. 1). Petitioner alleged that as a result of receiving a tetanus-diphtheria-acellular pertussis (“Tdap”) vaccine on August 22, 2017, she developed Guillain-Barré syndrome (“GBS”) with residual effects that persisted for more than six months. Id. On February 27, 2020, respondent filed a stipulation providing that a decision should be entered awarding compensation to petitioner. Stipulation (ECF No. 50). Respondent denies that the Tdap immunization caused or significantly aggravated petitioner’s alleged GBS or any other injury or condition. Id. at ¶ 6. Maintaining their respective positions, the parties nevertheless 1 Pursuant to the E-Government Act of 2002, see 44 U.S.C. § 3501 note (2012), because this opinion contains a reasoned explanation for the action in this case, I intend to post it on the website of the United States Court of Federal Claims. The Court’s website is at http://www.uscfc.uscourts.gov/aggregator/sources/7. Before the opinion is posted on the Court’s website, each party has 14 days to file a motion requesting redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). An objecting party must provide the Court with a proposed redacted version of the opinion. Id. If neither party files a motion for redaction within 14 days, the opinion will be posted on the Court’s website without any changes. Id. 2 The National Vaccine Injury Compensation Program is set forth in Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended, 42 U.S.C. §§ 300aa-1 to -34 (2012) (Vaccine Act or the Act). All citations in this decision to individual sections of the Vaccine Act are to 42 U.S.C.A. § 300aa. Case 1:18-vv-00622-UNJ Document 55 Filed 03/20/20 Page 2 of 7 now agree that the issues between them shall be settled and that a decision should be entered awarding compensation according to the terms of the stipulation attached hereto as Appendix A. Id. at ¶ 7. The stipulation awards: 1) A lump sum of $155,000.00, in the form of a check payable to petitioner. This amount represents compensation for all damages that would be available under 42 U.S.C. § 300aa-15(a). I adopt the stipulation as the decision of the Court in awarding damages. I hereby award compensation in the amount and on the terms set forth therein. Accordingly, the Clerk of the Court SHALL ENTER JUDGMENT in accordance with the terms of the parties’ stipulation.3 IT IS SO ORDERED. s/Thomas L. Gowen Thomas L. Gowen Special Master 3 Entry of judgment is expedited by each party’s filing notice renouncing the right to seek review. Vaccine Rule 11(a). 2 Case 1:18-vv-00622-UNJ Document 55 Filed 03/20/20 Page 3 of 7 Case 1:18-vv-00622-UNJ Document 55 Filed 03/20/20 Page 4 of 7 Case 1:18-vv-00622-UNJ Document 55 Filed 03/20/20 Page 5 of 7 Case 1:18-vv-00622-UNJ Document 55 Filed 03/20/20 Page 6 of 7 Case 1:18-vv-00622-UNJ Document 55 Filed 03/20/20 Page 7 of 7